OpenAI acquired Orchestra Bio, a drug development software startup, to bring AI-powered operations to life sciences R&D, the company announced.[1][2][3] Orchestra builds AI agents that help pharmaceutical teams monitor studies, track finances and resolve clinical trial scheduling issues, according to SiliconANGLE.[1] The startup’s staff and technology will join OpenAI’s Rosalind unit, which launched in April as a reasoning model for biology and drug discovery.[1] Terms were not disclosed, and OpenAI gave no timeline for when Orchestra’s agents will appear in its products.[1]
OpenAI acquires Orchestra Bio, a drug development software startup
Terms were not disclosed, and OpenAI gave no timeline for when Orchestra's agents will appear in its products.
1 primary · 2 independent · 0 commentary · 1 vendorSources
- OpenAI acquires Orchestra Bio to bring AI agents into drug development SiliconANGLE Independent
- OpenAI acquires startup Orchestra Bio to beef up its biotech business TechCrunch Independent
- OpenAI acquires Orchestra Bio OpenAI PrimaryVendor